BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

IRIDEX Corporation (IRIX) Announces Final Results of Its Tender Offer


12/14/2012 9:38:00 AM

MOUNTAIN VIEW, Calif., Dec. 14, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today the final results of its tender offer to purchase up to 487,500shares of its common stock at a purchase price of $4.10 per share, which expired at 5:00 p.m., New York City time, on Friday, December 7, 2012.

IRIDEX has accepted for payment an aggregate of 487,500shares of its common stock, including all "odd lots" properly tendered, at a purchase price of $4.10 per share, for a total cost of approximately $2 million. These shares represent approximately 5.5 percent of IRIDEX's currently issued and outstanding shares of common stock. Based on the final count by Computershare Inc., the depositary for the tender offer, 1,434,527 shares of IRIDEX common stock were properly tendered and not withdrawn (excluding any conditional tenders that were not accepted due to the specified condition not being satisfied). IRIDEX has been informed by the depositary that, after giving effect to the priority for "odd lots," the final pro-ration factor is approximately 32.9%. The depositary will promptly pay for the shares accepted for purchase and will return all other shares tendered.

The tender offer was made pursuant to an Offer to Purchase, dated November 7, 2012, as amended by Amendment No. 1 to the Offer to Purchase, dated November 13, 2012, and Letter of Transmittal, dated November 7, 2012, filed with the Securities and Exchange Commission.

The information agents are The Proxy Advisory Group, LLC and Allen & Caron Inc., and the depositary is Computershare Inc. For questions and information, please call the information agents toll-free at (888) 740-7130.

SOURCE IRIDEX Corporation


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->